Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Schizophr Res ; 191: 43-50, 2018 01.
Artigo em Inglês | MEDLINE | ID: mdl-28385587

RESUMO

One of the most robust electrophysiological features of schizophrenia is reduced mismatch negativity, a component of the event related potential (ERP) induced by rare and unexpected stimuli in an otherwise regular pattern. Emerging evidence suggests that mismatch negativity (MMN) is not the only ERP index of deviance detection in the mammalian brain and that sensitivity to deviant sounds in a regular background can be observed at earlier latencies in both the human and rodent brain. Pharmacological studies in humans and rodents have previously found that MMN reductions similar to those seen in schizophrenia can be elicited by N-methyl-d-aspartate (NMDA) receptor antagonism, an observation in agreement with the hypothesised role of NMDA receptor hypofunction in schizophrenia pathogenesis. However, it is not known how NMDA receptor antagonism affects early deviance detection responses. Here, we show that NMDA antagonism impacts both early and late deviance detection responses. By recording EEG in awake, freely-moving rats in a drug-free condition and after varying doses of NMDA receptor antagonist MK-801, we found the hypothesised reduction of deviance detection for a late, negative potential (N55). However, the amplitude of an early component, P13, as well as deviance detection evident in the same component, were increased by NMDA receptor antagonism. These findings indicate that late deviance detection in rats is similar to human MMN, but the surprising effect of MK-801 in increasing ERP amplitudes as well as deviance detection at earlier latencies suggests that future studies in humans should examine ERPs over early latencies in schizophrenia and after NMDA antagonism.


Assuntos
Variação Contingente Negativa/efeitos dos fármacos , Maleato de Dizocilpina/farmacologia , Potenciais Evocados Auditivos/efeitos dos fármacos , Antagonistas de Aminoácidos Excitatórios/farmacologia , Estimulação Acústica , Análise de Variância , Animais , Relação Dose-Resposta a Droga , Eletroencefalografia , Masculino , Ratos , Ratos Wistar
2.
J Transl Med ; 14(1): 123, 2016 05 06.
Artigo em Inglês | MEDLINE | ID: mdl-27154463

RESUMO

Chronic pain constitutes a challenge for the scientific community and a significant economic and social cost for modern societies. Given the failure of current drugs to effectively treat chronic pain, which are based on suppressing aberrant neuronal excitability, we propose in this review an integrated approach that views pain not solely originating from neuronal activation but also the result of a complex interaction between the nervous, immune, and endocrine systems. Pain assessment must also extend beyond measures of behavioural responses to noxious stimuli to a more developmentally informed assessment given the significant plasticity of the nociceptive system during the neonatal period. Finally integrating the concept of perinatal programming into the pain management field is a necessary step to develop and target interventions to reduce the suffering associated with chronic pain. We present clinical and animal findings from our laboratory (and others) demonstrating the importance of the microbial and relational environment in programming pain responsiveness later in life via action on hypothalamo-pituitary adrenal (HPA) axis activity, peripheral and central immune system, spinal and supraspinal mechanisms, and the autonomic nervous system.


Assuntos
Sistema Endócrino/patologia , Sistema Nervoso/imunologia , Sistema Nervoso/patologia , Dor/patologia , Animais , Sistema Endócrino/fisiopatologia , Humanos , Sistema Hipotálamo-Hipofisário/patologia , Sistema Hipotálamo-Hipofisário/fisiopatologia , Sistema Nervoso/fisiopatologia , Nociceptividade , Dor/fisiopatologia , Manejo da Dor , Sistema Hipófise-Suprarrenal/patologia , Sistema Hipófise-Suprarrenal/fisiopatologia
3.
Respir Physiol Neurobiol ; 204: 21-7, 2014 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-25090960

RESUMO

The prefrontal cortex is one of the key areas of the central mechanism of cardiovascular and respiratory control. Disinhibition of the prelimbic medial prefrontal cortex elicits tachypnoeic responses in anesthetized rats (Hassan et al., J. Physiol. 591: 6069-6088, 2013). The current study examines the effects of inhibition of the prelimbic prefrontal cortex during presentation of stressors of various lengths and intensities in conscious unrestrained rats. 8 Wistar rats were implanted with bilateral guide cannulas targeting the prelimbic prefrontal cortex and received microinjections of either saline of GABAA agonist muscimol prior to recording sessions. Inhibition of the prelimbic prefrontal cortex significantly attenuated respiratory responses to a novel environment stress, 30s light stimulus and restraint stress. It did not affect respiratory responses to 500 ms acoustic stimuli of varying intensities (40-90 dB). We conclude that the prelimbic prefrontal cortex contributes to generation of tachypnoeic responses to prolonged stressors, but does not contribute to respiratory arousal in response to brief stressors.


Assuntos
Córtex Pré-Frontal/fisiopatologia , Respiração , Estresse Psicológico/fisiopatologia , Estimulação Acústica/métodos , Animais , Cateteres de Demora , Modelos Animais de Doenças , Agonistas de Receptores de GABA-A/farmacologia , Masculino , Microinjeções , Muscimol/farmacologia , Estimulação Luminosa/métodos , Pletismografia , Córtex Pré-Frontal/efeitos dos fármacos , Ratos Wistar , Receptores de GABA-A/metabolismo , Respiração/efeitos dos fármacos , Restrição Física , Estresse Psicológico/tratamento farmacológico , Taquipneia/tratamento farmacológico , Taquipneia/fisiopatologia , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA